CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 222 enrolled
Drug / intervention
teriparatide +4 moredrug
Likely dose
BA058 20 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00542425
NCT00542425Phase 2Completed
CompareCT.gov

A Randomized, Parallel-Group, Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis

Radius Health, Inc.·interventional·Posted Oct 11, 2007·Updated Oct 30, 2017

In Brief

A Phase 2 clinical trial evaluating teriparatide, Placebo, and 3 other interventions for Osteoporosis. Completed, enrolled 222 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether BA058 is effective in building bone in postmenopausal women with osteoporosis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 11, 2007
Enrollment StartApr 1, 2007
Primary CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 18.7 years ago

Interventions

teriparatidedrug

teriparatide 20 µg subcutaneous daily

Placebodrug

Placebo subcutaneous daily

BA058 20 µgdrug

BA058 20 µg subcutaneous daily

BA058 40 µgdrug

BA058 40 µg subcutaneous daily

BA058 80 µgdrug

BA058 80 µg subcutaneous daily